Computationally restoring the potency of a clinical antibody against Omicron.

ABSTRACT: The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs^1-3 and revealed how quickly viral escape can curtail effective options^4,5. When the SARS-CoV-2 Omicron variant emerged in 2021, many antibody drug products lost potency, including Evusheld and its constituent, cilgavimab^4-6. Cilgavimab, like its progenitor COV2-2130, is a class 3 antibody that is compatible with other antibodies in combination⁴ and is challenging to replace with existing approaches. Rapidly modifying such high-value antibodies to restore efficacy against emerging variants is a compelling mitigation strategy. We sought to redesign and renew the efficacy of COV2-2130 against Omicron BA.1 and BA.1.1 strains while maintaining

SUBMITTER: Desautels TA 

PROVIDER: S-EPMC11111397 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature